title: MicroRNA‑133a and microRNA‑326 co‑contribute to hepatocellular carcinoma 5‑fluorouracil and cisplatin sensitivity by directly targeting B‑cell lymphoma‑extra large.
abstract: Chemotherapy is one of the most common treatments used for hepatocellular carcinoma (HCC), which effectively improves outcome and reduces tumor recurrence. However, the drug resistance mechanisms involved in chemotherapy, which is the predominant challenge in HCC treatment, remain to be fully elucidated. Therefore, there is an urgent requirement for the identification of novel therapeutic strategies or drugs. MicroRNAs (miRs) have become an area of interest, and in the present study, the effects of miR‑133a and miR‑326 on HepG2 cells, and their function on B‑cell lymphoma‑extra large (Bcl‑xl) in HepG2 cells were investigated. Using computational programs, Bcl‑xl was predicted as the common target gene of miR‑133a and miR‑326. A dual‑luciferase reporter assay was used to verify the target genes of miRs. The mRNA and protein levels of Bcl‑xl were observed to be downregulated following transfection with miR‑133a or miR‑326 mimics. Combining miR‑133a or miR‑326 with 5‑fluorouracil (5‑FU) or cisplatin (DDP) resulted in increased cell death. The results of the present study indicated that miR‑133a, miR‑326 and Bcl‑xl acted protectively against the apoptosis, induced by 5‑FU or DDP, in HepG2 cells. This suggested the potential use of miRs either as ancillary anti‑cancer drugs or as anti‑cancer drugs themselves.
authors.affiliation: Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Jin
authors.initials: J
authors.lastname: Ma
authors.affiliation: Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Ting
authors.initials: T
authors.lastname: Wang
authors.affiliation: Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Rui
authors.initials: R
authors.lastname: Guo
authors.affiliation: Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Yang
authors.affiliation: Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Jie
authors.initials: J
authors.lastname: Yin
authors.affiliation: Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Jia
authors.initials: J
authors.lastname: Yu
authors.affiliation: Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Xiang
authors.affiliation: Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Xia
authors.initials: X
authors.lastname: Pan
authors.affiliation: Institute of Clinical Medicine, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Xuyu
authors.initials: X
authors.lastname: Zu
authors.affiliation: Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Cuiying
authors.initials: C
authors.lastname: Peng
authors.affiliation: Cardiology Department, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Huifang
authors.initials: H
authors.lastname: Tang
authors.affiliation: Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan 421001, P.R. China.
authors.forename: Xiaoyong
authors.initials: X
authors.lastname: Lei
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D015536:Down-Regulation; D005472:Fluorouracil / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic; D056945:Hep G2 Cells / Q000187:drug effects; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D015854:Up-Regulation; D051020:bcl-X Protein / Q000235:genetics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; C494811:BCL2L1 protein, human; C548234:MIRN133 microRNA, human; C545322:MIRN326 microRNA, human; D035683:MicroRNAs; D012333:RNA, Messenger; D051020:bcl-X Protein; D002945:Cisplatin; D005472:Fluorouracil